JP7602217B2 - ビスホスホネート・キノロン複合体及びそれらの用途 - Google Patents

ビスホスホネート・キノロン複合体及びそれらの用途 Download PDF

Info

Publication number
JP7602217B2
JP7602217B2 JP2019515787A JP2019515787A JP7602217B2 JP 7602217 B2 JP7602217 B2 JP 7602217B2 JP 2019515787 A JP2019515787 A JP 2019515787A JP 2019515787 A JP2019515787 A JP 2019515787A JP 7602217 B2 JP7602217 B2 JP 7602217B2
Authority
JP
Japan
Prior art keywords
group
substituted
bone
ciprofloxacin
osteomyelitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515787A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518792A5 (https=
JP2019518792A (ja
Inventor
フランク、 エイチ． エベティノ、
シュティン スン、
マーク、 ダブリュ． ランディ、
チャールズ、 イー． マッケンナ、
エリック リチャード、
パリッシュ セドギザデー、
ケイバン サドレラフィ、
Original Assignee
バイオビンク エルエルシー
ユニバーシティ オブ サザン カリフォルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオビンク エルエルシー, ユニバーシティ オブ サザン カリフォルニア filed Critical バイオビンク エルエルシー
Publication of JP2019518792A publication Critical patent/JP2019518792A/ja
Publication of JP2019518792A5 publication Critical patent/JP2019518792A5/ja
Priority to JP2022117577A priority Critical patent/JP2022166008A/ja
Priority to JP2023171669A priority patent/JP2023181185A/ja
Application granted granted Critical
Publication of JP7602217B2 publication Critical patent/JP7602217B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
JP2019515787A 2016-06-03 2017-06-02 ビスホスホネート・キノロン複合体及びそれらの用途 Active JP7602217B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022117577A JP2022166008A (ja) 2016-06-03 2022-07-22 ビスホスホネート・キノロン複合体及びそれらの用途
JP2023171669A JP2023181185A (ja) 2016-06-03 2023-10-02 ビスホスホネート・キノロン複合体及びそれらの用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662345370P 2016-06-03 2016-06-03
US62/345,370 2016-06-03
US201662357727P 2016-07-01 2016-07-01
US62/357,727 2016-07-01
US201762448060P 2017-01-19 2017-01-19
US62/448,060 2017-01-19
PCT/US2017/035764 WO2017210611A1 (en) 2016-06-03 2017-06-02 Bisphosphonate quinolone conjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022117577A Division JP2022166008A (ja) 2016-06-03 2022-07-22 ビスホスホネート・キノロン複合体及びそれらの用途

Publications (3)

Publication Number Publication Date
JP2019518792A JP2019518792A (ja) 2019-07-04
JP2019518792A5 JP2019518792A5 (https=) 2019-08-15
JP7602217B2 true JP7602217B2 (ja) 2024-12-18

Family

ID=60479075

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019515787A Active JP7602217B2 (ja) 2016-06-03 2017-06-02 ビスホスホネート・キノロン複合体及びそれらの用途
JP2022117577A Withdrawn JP2022166008A (ja) 2016-06-03 2022-07-22 ビスホスホネート・キノロン複合体及びそれらの用途
JP2023171669A Pending JP2023181185A (ja) 2016-06-03 2023-10-02 ビスホスホネート・キノロン複合体及びそれらの用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022117577A Withdrawn JP2022166008A (ja) 2016-06-03 2022-07-22 ビスホスホネート・キノロン複合体及びそれらの用途
JP2023171669A Pending JP2023181185A (ja) 2016-06-03 2023-10-02 ビスホスホネート・キノロン複合体及びそれらの用途

Country Status (4)

Country Link
EP (1) EP3464307A4 (https=)
JP (3) JP7602217B2 (https=)
CN (1) CN110114366A (https=)
WO (1) WO2017210611A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210611A1 (en) * 2016-06-03 2017-12-07 Biovinc, Llc. Bisphosphonate quinolone conjugates and uses thereof
KR20180115979A (ko) * 2017-04-14 2018-10-24 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
US12285489B2 (en) * 2018-06-26 2025-04-29 Frank Hallock Ebetino Bone targeted antimicrobial oxazolidinone related compounds, formulations thereof, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536911A (ja) 2005-04-21 2008-09-11 ターガンタ セラピュティクス，インコーポレイティド ホスホン酸処理フルオロキノロン、その抗菌類似体および骨および関節感染の予防および治療方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
IE912115A1 (en) * 1990-06-25 1992-01-01 Takeda Chemical Industries Ltd Bisphosphonic acid derivatives, their production and use
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
FI945595A7 (fi) * 1992-05-29 1994-11-28 Procter & Gamble Pharmaceuticals Inc Tiosubstituoituja typpipitoisia heterosyklisiä fosfonaattiyhdisteitä e pänormaalin kalsium- ja fosfaattiaineenvaihdunnan hoitamiseksi
US6333424B1 (en) * 1996-10-09 2001-12-25 Eliza Nor Biopharmaceuticals, Inc. Therapeutic derivatives of diphosphonates
US8586781B2 (en) * 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
JP5161872B2 (ja) * 2006-05-12 2013-03-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 細菌感染に対する抗微生物療法
CL2007003332A1 (es) * 2006-11-24 2008-06-20 Actelion Pharmaceuticals Ltd Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
WO2010071826A2 (en) * 2008-12-19 2010-06-24 University Of Florida Research Foundation, Inc. Methods for treating osteoclast-related disease, compounds and compositions thereof
US20140051652A1 (en) * 2012-08-20 2014-02-20 Kingsley Yianomah Quartey Treatment for Migraine Headache
WO2017210611A1 (en) * 2016-06-03 2017-12-07 Biovinc, Llc. Bisphosphonate quinolone conjugates and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536911A (ja) 2005-04-21 2008-09-11 ターガンタ セラピュティクス，インコーポレイティド ホスホン酸処理フルオロキノロン、その抗菌類似体および骨および関節感染の予防および治療方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ，２００８年，５１（２１），ｐ．６９５５－６９６９
新実験化学講座１５，１９７６年，丸善株式会社，１０７４頁

Also Published As

Publication number Publication date
CA3028343A1 (en) 2017-12-07
JP2019518792A (ja) 2019-07-04
EP3464307A4 (en) 2020-01-22
CN110114366A (zh) 2019-08-09
JP2023181185A (ja) 2023-12-21
EP3464307A1 (en) 2019-04-10
WO2017210611A1 (en) 2017-12-07
JP2022166008A (ja) 2022-11-01

Similar Documents

Publication Publication Date Title
US20240182504A1 (en) Bisphosphonate quinolone conjugates and uses thereof
JP2023181185A (ja) ビスホスホネート・キノロン複合体及びそれらの用途
Sedghizadeh et al. Design, synthesis, and antimicrobial evaluation of a novel bone-targeting bisphosphonate-ciprofloxacin conjugate for the treatment of osteomyelitis biofilms
US20210393666A1 (en) Methods and compositions for treating oral mucositis
JP7501960B2 (ja) ビスホスホネート・キノロン複合体及びそれらの用途
CA3028343C (en) Bisphosphonate quinolone conjugates and uses thereof
OA11655A (en) Use of organophosphorous compounds for producing medicaments for the therapeutic and prophylactic treatment of infections or as a fungicide, bactericide or herbicide for plants.
US11400104B2 (en) Skeletal removal of bisphosphonates
Huang Investigating the role of bisphosphonates on bone cells and the potential of ionic therapy to restore bone regeneration in osteonecrosis of the jaw
US12285489B2 (en) Bone targeted antimicrobial oxazolidinone related compounds, formulations thereof, and uses thereof
Kato Biological Profile of Fast-Setting Calcium Silicate-Based Cements: In Vitro and Ex Vivo Evaluation
Veena Evaluation of an aminobisphosphonate (alendronate) as local drug delivery system in the management of periodontal osseous defects-a clinical and radiological study
ATE504332T1 (de) Verbindungen, zusammensetzungen, formulierungen und herstellungsverfahren dafür, behandlungsverfahren, handhabung von übersäuerung und verwandte erkrankungen
AU2005202737B2 (en) Use of chemotherapeutic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220722

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220901

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220922

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220927

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221125

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241125

R150 Certificate of patent or registration of utility model

Ref document number: 7602217

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150